These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 32643913)
1. Assessment of serotonin concentration in patients with a small-intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues. Gut P; Czarnywojtek A; Sawicka-Gutaj N; Ruchała M Pol Arch Intern Med; 2020 Oct; 130(10):903-905. PubMed ID: 32643913 [No Abstract] [Full Text] [Related]
2. Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues. Gut P; Ruchała M Neuro Endocrinol Lett; 2019 Dec; 40(7-8):315-318. PubMed ID: 32304367 [TBL] [Abstract][Full Text] [Related]
3. An update of lanreotide acetate for treatment of adults with carcinoid syndrome. Guadalupe E; Deshpande HA; Stein SM Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440 [TBL] [Abstract][Full Text] [Related]
4. Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues. Kasi PM Drugs Today (Barc); 2018 Jul; 54(7):423-432. PubMed ID: 30090879 [TBL] [Abstract][Full Text] [Related]
8. Grade 3 Neuroendocrine Tumor (G3 NET) in a Background of Multiple Serotonin Cell Neoplasms of the Ileum Associated with Carcinoid Syndrome and Aggressive Behavior. Capuano F; Grami O; Pugliese L; Paulli M; Pietrabissa A; Solcia E; Vanoli A Endocr Pathol; 2018 Dec; 29(4):369-373. PubMed ID: 30076568 [TBL] [Abstract][Full Text] [Related]
9. [Somatostatin analogs in the treatment of carcinoid syndrome: a case report and review of literature]. Junik R; Kamińska A; Kamiński M; Ruprecht Z Pol Arch Med Wewn; 2003 Sep; 110(3):997-1001. PubMed ID: 14699693 [TBL] [Abstract][Full Text] [Related]
13. Somatostatin analogues do not prevent carcinoid crisis. Guo LJ; Tang CW Asian Pac J Cancer Prev; 2014; 15(16):6679-83. PubMed ID: 25169508 [TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome. Koumarianou A; Daskalakis K; Tsoli M; Kaltsas G; Pavel M J Neuroendocrinol; 2022 Jul; 34(7):e13174. PubMed ID: 35794780 [TBL] [Abstract][Full Text] [Related]
15. Somatostatin does not prevent serotonin release and flushing during chemoembolization of carcinoid liver metastases. Zimmer C; Kienbaum P; Wiesemes R; Peters J Anesthesiology; 2003 Apr; 98(4):1007-11. PubMed ID: 12657865 [No Abstract] [Full Text] [Related]